方法对比

	自适应剂量-反应分析	自适应II期临床试验
领域	流行病学	流行病学
方法族	Process / pipeline	Process / pipeline
起源年份	2000s (key papers 2005–2007; ICH E4 guidance 1994 for classical dose-response)	1994 (formal framework); widespread adoption 2000s–2010s
提出者	Frank Bretz, José Pinheiro and colleagues; foundational MCP-Mod framework	Peter Bauer & Klaus Kohne (formal statistical framework, 1994); broader adaptive trial methodology developed through FDA and ICH guidance in the 2000s
类型	Adaptive statistical design and analysis	Experimental clinical trial design
开创性文献	Bretz, F., Pinheiro, J. C., & Branson, M. (2005). Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics, 61(3), 738-748.	Bauer, P., & Kohne, K. (1994). Evaluation of experiments with adaptive interim analyses. Biometrics, 50(4), 1029–1041.
别名	adaptive DRA, adaptive dose-finding analysis, adaptive exposure-response analysis, adaptive D-R modeling	Adaptive Ph II trial, seamless adaptive Phase II, adaptive dose-finding trial, response-adaptive Phase II
相关	6	1
摘要	Adaptive dose-response analysis combines pre-specified dose-response modeling with planned interim looks that allow modifications — such as dropping ineffective doses or reallocating sample size — while maintaining statistical integrity. The most widely cited framework is MCP-Mod (Multiple Comparisons and Modeling), endorsed by the EMA and FDA as a fit-for-purpose methodology for dose-finding studies in drug development.	An adaptive Phase II clinical trial is a prospective experimental design in which pre-specified rules allow the study protocol to be modified — such as dropping arms, adjusting sample size, or narrowing the patient population — based on accumulating interim data, without inflating the Type I error rate. The design is widely used in early-phase drug development to screen candidate doses or treatments efficiently while preserving statistical validity.